Joline Si Jing Lim

5PUBLICATIONS
35CO-AUTHORS
Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 23, 2024
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).

Nicholas Turner, Cristina Saura, Philippe Aftimos

|Feb 16, 2023
Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials.

Jerold Loh, Jiaxuan Wu, Jenny Chieng

|Feb 06, 2023
Immune checkpoint inhibitor combinations-current and emerging strategies.

Robert J Walsh, Raghav Sundar, Joline S J Lim

|Apr 01, 2022
Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer.

Joline S J Lim, Andrea L A Wong, Samuel G W Ow

|Sep 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.

Javier Pascual, Joline S J Lim, Iain R Macpherson

Pageof 1

Frequent Collaborators

3 joint publications

Raghav Sundar

2 joint publications

Cheng Ean Chee

1 joint publications

Javier Pascual

1 joint publications

Iain R Macpherson